Bone Biologics Corporation (BBLG) vs China SXT Pharmaceuticals, Inc. (SXTC)

A side-by-side comparison of Bone Biologics Corporation and China SXT Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

BBLG

Bone Biologics Corporation

$843637

$0.47HealthcareDelayed quote: Oct 6, 2026, 2:30 PM EDT

SXTC

China SXT Pharmaceuticals, Inc.

$742225

$1.39HealthcareDelayed quote: Oct 6, 2026, 2:45 PM EDT

Total return — BBLG vs SXTC

growth of $100 · dividends reinvested · last 5y

BBLG -100.0% (-80.5%/yr)SXTC -100.0% (-95.2%/yr)BBLG compounded faster over this window

Log scale — wide-divergence pair

BBLG SXTC

Metrics side by side

Total return (annualized)

Metric	BBLG	SXTC
Total return (1Y)	-80.44%	N/A
Total return CAGR (3Y)	-73.93%	N/A

SXTC is an index fund, so valuation, profitability, and per-company growth metrics don't apply — the head-to-head here is total return (price plus reinvested dividends).

Go deeper

Full BBLG analysis Full SXTC analysis Interactive comparison tool

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.